Bhubaneswar: Odisha began the construction work of a vaccine production unit at Andharua on the outskirts of Bhubaneswar and a target has been set to commence production of Covaxin by June 2022.
The project was announced after a state-level Bio-Tech implementation committee meeting was held virtually under the chairmanship of Chief Secretary Suresh Chandra Mahapatra.
The construction of the vaccine production unit because of IDCO’s “smooth land allotment process” and “ease of doing business reforms”, stated the release further
The required statutory clearances & permissions have also been granted for this.
Around Rs 15 crore was allocated under the ‘Fund of Funds’ of MSME department for providing equity support to the incubating units in Biotechnology sector,” said Mishra.
The company has taken up the development and production of new or improved vaccines against severe Rotavirus Diarrhoea, Malaria, Japanese Encephalitis, Rabies, Pandemic Influenza and drug resistant Staphylococcus aureus.
The extension of subsidies needs to be managed professionally for optimizing the outcomes.
Chairman and Managing Director IDCO Sanjay Singh said a state-of-the-art hub incubation centre has come up near Infocity, Bhubaneswar, where two floors with around 28,000 sqft space can be made available for incubation facilities.